Literature DB >> 13680524

Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Brian J Miller1, Daolong Wang, Ralf Krahe, Fred A Wright.   

Abstract

Somatic loss of heterozygosity (LOH) has been widely reported in breast cancer as a means of identifying putative tumor-suppressor genes. However, individual studies have rarely spanned more than a single chromosome, and the varying criteria used to declare LOH complicate efforts to formally differentiate regions of consistent versus sporadic (random) loss. We report here the compilation of an extensive database from 151 published LOH studies of breast cancer, with summary data from >15,000 tumors and primary allelotypes from >4,300 tumors. Allelic loss was evaluated at 1,168 marker loci, with large variation in the density of informative observations across the genome. Using studies in which primary allelotype information was available, we employed a likelihood-based approach with a formal chromosomal instability and selection model. The approach seeks direct evidence for preferential loss at each locus compared with nearby loci, accounts for heterogeneity across studies, and enables the direct comparison of candidate regions across the genome. Striking preferential loss was observed (in descending order of significance) in specific regions of chromosomes 7q, 16q, 13q, 17p, 8p, 21q, 3p, 18q, 2q, and 19p, as well as other regions, in many cases coinciding with previously identified candidate genes or known fragile sites. Many of these observations were not possible from any single LOH study, and our results suggest that many previously reported LOH results are not systematic or reproducible. Our approach provides a comparative framework for further investigation of regions exhibiting LOH and identifies broad genomic regions for which there exist few data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680524      PMCID: PMC1180599          DOI: 10.1086/378522

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  103 in total

1.  Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families.

Authors:  S Seitz; K Rohde; E Bender; A Nothnagel; K Kölble; P M Schlag; S Scherneck
Journal:  Oncogene       Date:  1997-02-13       Impact factor: 9.867

2.  Sequence mapping by electronic PCR

Authors:  Gregory D Schuler
Journal:  Genome Res       Date:  1997-05       Impact factor: 9.043

3.  Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.

Authors:  F Kerangueven; F Eisinger; T Noguchi; F Allione; V Wargniez; C Eng; G Padberg; C Theillet; J Jacquemier; M Longy; H Sobol; D Birnbaum
Journal:  Oncogene       Date:  1997-01-23       Impact factor: 9.867

4.  Loss of heterozygosity on chromosome arm 16q in breast cancer metastases.

Authors:  K Driouch; F Dorion-Bonnet; M Briffod; M H Champéme; M Longy; R Lidereau
Journal:  Genes Chromosomes Cancer       Date:  1997-07       Impact factor: 5.006

5.  Deletion mapping in breast tumor cell lines points to two distinct tumor-suppressor genes in the 1p32-pter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma.

Authors:  I Bieche; A Khodja; R Lidereau
Journal:  Oncol Rep       Date:  1998 Jan-Feb       Impact factor: 3.906

Review 6.  Somatic mutations that contribute to breast cancer.

Authors:  R Callahan
Journal:  Biochem Soc Symp       Date:  1998

7.  Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region.

Authors:  T Chen; A Sahin; C M Aldaz
Journal:  Cancer Res       Date:  1996-12-15       Impact factor: 12.701

Review 8.  Hereditary breast cancer.

Authors:  L W Ellisen; D A Haber
Journal:  Annu Rev Med       Date:  1998       Impact factor: 13.739

9.  Detailed deletion mapping of chromosome arm 3p in breast cancers: a 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors.

Authors:  S Matsumoto; F Kasumi; G Sakamoto; M Onda; Y Nakamura; M Emi
Journal:  Genes Chromosomes Cancer       Date:  1997-11       Impact factor: 5.006

10.  PRLTS gene alterations in human prostate cancer.

Authors:  A Komiya; H Suzuki; T Ueda; S Aida; N Ito; T Shiraishi; R Yatani; M Emi; K Yasuda; J Shimazaki; H Ito
Journal:  Jpn J Cancer Res       Date:  1997-04
View more
  33 in total

1.  Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.

Authors:  Thomas P Ahern; Per Damkier; Søren Feddersen; Anders Kjærsgaard; Timothy L Lash; Stephen Hamilton-Dutoit; Cathrine Bredal Lythjohan; Bent Ejlertsen; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Acta Oncol       Date:  2020-04-30       Impact factor: 4.089

2.  Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma.

Authors:  Jin Li; Lyndsay Harris; Harvey Mamon; Matthew H Kulke; Wei-Hua Liu; Penny Zhu; G Mike Makrigiorgos
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

Review 3.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

4.  BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer.

Authors:  Rekha Rai; Hui Dai; Asha S Multani; Kaiyi Li; Koei Chin; Joe Gray; John P Lahad; Jiyong Liang; Gordon B Mills; Funda Meric-Bernstam; Shiaw-Yih Lin
Journal:  Cancer Cell       Date:  2006-07-27       Impact factor: 31.743

5.  The overexpression of MCPH1 inhibits cell growth through regulating cell cycle-related proteins and activating cytochrome c-caspase 3 signaling in cervical cancer.

Authors:  Li Mai; Faping Yi; Xiaoyan Gou; Ji Zhang; Changdong Wang; Geli Liu; Youquan Bu; Chengfu Yuan; Linman Deng; Fangzhou Song
Journal:  Mol Cell Biochem       Date:  2014-03-15       Impact factor: 3.396

6.  Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.

Authors:  Frank Weber; Lei Shen; Koichi Fukino; Attila Patocs; George L Mutter; Trinidad Caldes; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-04-12       Impact factor: 11.025

7.  SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication.

Authors:  Pegah Johansson; Jessie Jeffery; Fares Al-Ejeh; Renèe B Schulz; David F Callen; Raman Kumar; Kum Kum Khanna
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

8.  SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.

Authors:  Stephanie Hammerich-Hille; Benny A Kaipparettu; Anna Tsimelzon; Chad J Creighton; Shiming Jiang; Jose M Polo; Ari Melnick; Rene Meyer; Steffi Oesterreich
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

9.  Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Carol L Rosenberg; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Clin Epidemiol       Date:  2010-10-22       Impact factor: 4.790

10.  F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage.

Authors:  Manas K Santra; Narendra Wajapeyee; Michael R Green
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.